Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 17.07% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 52.67B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 171.67%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 171.67%.
Undervalued
The company’s latest PE is 12.00, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 225.52M shares, decreasing 13.87% quarter-over-quarter.
Held by Sarah Ketterer
Star Investor Sarah Ketterer holds 9.63M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.47.